Goldman Sachs analyst Chris Shibutani initiated coverage of Vaxcyte (PCVX) with a Buy rating and $135 price target The firm says clinical data for the company’s lead programs provide a “foundation for viewing” its core longer-term fundamentals as “strongly positive.” The recent relative underperformance of the shares, driven primarily by uncertainties deriving from broader macro and healthcare policy-related uncertainties, creates an “especially attractive entry point,” the analyst tells investors in a research note. Goldman believes Vaxcyte’s upcoming data in Q1 for VAX-24 in the infant and pediatric population “provides a potentially high impact near-term catalyst.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte initiates Phase 2 study of VAX-31
- Trump expected to pick Martin Makary to head FDA, Reuters reports
- Vaccine makers fall after Trump nominates RFK to head HHS
- Vaxcyte provides regulatory updates on VAX-31 programs
- Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges